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A novel, integrated approach for automated sample handling in
drug discovery bioanalysis is described. The process includes
aspects of animal study design, biological sample collection,
sample processing and high-throughput APILC/MS operating in
under multiple reaction monitoring (MRM). A semi-automated
96-well liquidºliquid extraction technique for biological £uid
sample preparation was developed and used in conjunction with
the integrated sample-handling approach. One plate of samples
could be prepared within 1.5h compared with 4h for a manual
approach, and the resulting 96-well plate of extracts was directly
compatible with the LC/MS. Feasibility studies for the develop-
ment of the process included sample collection map generation and
information management, sample collection formatting, evaluation
of alternative dilution schemes for high-concentration samples,
choice of biological £uid, and evaluating the capabilities of the
two liquid-handling workstations. Numerous comparisons between
the new approach and conventional sample-handling approaches
gave equivalent drug-quantitation results for several example
compounds. This new sampling process has approximately doubled
the e¤ciency (as measured by studies assayed per month) of drug
discovery bioanalysis in our laboratory. The approach was also
used in conjunction with time-of-£ight mass spectrometry instru-
mentation (LC/TOF/MS) to quantify and characterize the
disposition of simultaneously dosed example drug compounds in
the rat. Likely strategies for future automated sample preparation
workstations are described.
Introduction
Emerging technologies such as combinatorial chemistry
[1, 2] and cassette dosing [3, 4] have accelerated the
drug-discovery process. In response, the demand for
bioanalytical practice has resulted in faster analytical
techniques and higher preparation capacity. At present,
one of the most widely used techniques in bioanalytical
laboratories supporting pharmacokinetics, drug transport
and metabolism is liquid chromatography-tandom mass
spectrometry (LC/MS/MS) with mutiple-channel-mon-
itoring (MRM) [5, 6]. The technique has greatly
facilitated bioanalytical work, so that the most time-
consuming and labour-intensive steps are still associated
with sample handling. Recent studies have reported
signi® cant improvements in the sample-preparation pro-
cess. One area showing much progress is the automation
of sample preparation by using various liquid-handling
workstations. These workstations replaced manual liquid
transfers and use parallel sample preparation (e.g. 96-
well plate) for higher sample throughput [7± 9]. Work-
stations have proven useful by improving the sample
preparation process through more eå ective extractions
[10], better automation of extractions [11], reduction in
scale [12] and use of automated method development
[13]. These advances are reducing method development
time and, in some aspects, increasing assay quality. These
eå orts, however, only focus on the sample preparation
step of the bioanalytical process. Other than those
sampling approaches utilized for on-line, in vivo micro-
dialysis sampling [14], there appears to be no recent
papers describing a comprehensive sample handling for
the drug-discovery process.
In drug discovery, processes closely associated with bio-
analysis (BA) are study design and animal study conduct/
sample collection. These three processes are often driven
by groups operating sequentially but independently, or
by equivalent, separate groups operating in parallel.
Lack of integration or standardization in sample collec-
tion and information delivery present in these processes
can result in ineæ ciency for sample collection/processing
and break-down in information between the three
groups. For example, an analytical chemist could spend
considerable time transferring samples to a 96-well for-
mat before automated processing on a liquid-handling
workstation. At this point, it seems reasonable that
greater process eæ ciency could be attained if a closer
relationship between the separate processes of study de-
sign, sample generation and bioanalytical sample prep-
aration were developed.
This paper reports on an integrated sample-handling
process for bioanalytical discovery, based on biological
sample collection directly in a 96-well format and taking
into account the front-end preclinical protocol design and
sample-processing requirements. The purpose was to
demonstrate standardized and eæ cient sample-handling
procedures for drug discovery. A comparison of diå erent
sample collection formats and sample-processing options
is also reported. Characteristic pharmacokinetic data
obtained from the diå erent approaches are also discussed
and compared for four example compounds.
Experimental
Analyte test system, reagents and LC/MS experimental conditions
Analytes and reagents, such as drugs, organic solvents,
blank rat plasma and HPLC mobile phase, were pur-
chased or prepared from the same sources as those in
Zhang et al. [15]. Brie¯ y, diphenhydramine, desipramine,
chlorpheniramine and trimipramine were the four com-
pounds tested here. Lidocain was added as an internal
standard. The same LC/MS apparatus and sample
Journal of Automated Methods & Management in Chemistry
Vol. 24, No. 1 (January–February 2002) pp. 1–7
Journal of Automated Methods & Management in Chemistry ISSN 1463± 9246 print/ISSN 1464± 5068 online # 2002 ISLAR
http://www.tandf.co.uk/journals
DOI: 10.1080/14639240110092567
{This paper was initially presented at the ISLAR 2000 Conference and
is reproduced here by kind permission of Zymark Corporation.
1preparation conditions as those in [15] were also used
here.
Apparatus
A MultiProbe II (Packard Instruments, Meriden, CT,
USA) was used to transfer plasma and serum. It was
equipped with an x, y, z-coordinate robotic arm with four
sampling tips. It was optimized for aspiration and
dispensation of diå erent liquids with varying viscosities.
Small conductive disposable tips were used together with
the liquid-sensing function when aspirating and dispen-
sing (3mm below the liquid surface). A Tomtec Quadra
96 model 320 (Hamden, CT, USA) was used to handle
all 96-well parallel-liquid transfers such as internal
standard addition, organic solvent addition, organic
layer transfers and reconstitution after nitrogen dry
down. This semi-automated 96-well liquid-extraction
approach using a Tomtec workstation was introduced
in [15]. An Eppendorf centrifuge (model 5810R, Ham-
burg, Germany) operating at 3000rpms was a refriger-
ated bench-top centrifuge that could accommodate 96-
well plates.
Drug administration and sample collection
Two studies were conducted to evaluate potential stra-
tegies for integration of the sample collection step with
sample processing. In each experiment, six male Wistar
rats (three for oral, three for intravenous) were dosed.
The animals were fasted for 12h before drug administra-
tion. Drugs I± IV were dissolved in a 10% ethanol
aqueous solution (4mgml¡1) for oral gavage. Intrave-
nous infusion solutions contained 4mgml¡1 of each drug
dissolved in a mixture of ethanol:dextrose (5%) aqueous
solution (10:90v/v). The total dose was 10mgkg¡1 for
both oral and intravenous treatments. The time points
for collection in each study were predose, 30min, 1h, 2, 4
and 6h. Whole-blood samples were collected in either
serum or plasma (with sodium heparin) separator tubes.
Samples were placed directly into individual 1.1-ml
polypropylene tubes in a 96-well tube-rack format
(Costar, Cambridge, MA, USA). The arrangement of
the sample tubes in the rack will be discussed below.
For the ® rst study, two plates of plasma samples were
collected with ¹ 400 ml blood at each time point. In the
® rst plate, exact plasma volumes of 25ml (30min and 1h
samples) or 100ml (predose, 2h, 4 and 6h) were trans-
ferred to tubes in the 96-well plate rack. To the second
plate, the remaining volumes of ¹ 120± 220 ml were trans-
ferred and frozen …¡208C†.
For the second study, three rats were dosed intravenously
with the same four drugs. Both serum and plasma
samples were harvested from the same animal, trans-
ferred into respective 96-well tube plates and frozen
…¡208C† for quantitative comparison at a later time.
Pharmacokinetic parameters were calculated using Win-
Nonlin software (v. 2.1, Pharsight Corporation, Palo
Alto, CA, USA).
Experimental overview
Multiprobe precision assessment. Testing the precision of
liquid transfer by the MultiProbe II was performed for
plasma and serum. Assessment involved gravimetric
determinations of transfer volumes.
Parallelism assessment. To evalute the eå ect of diå erent
dilution approaches on quantitation, blank rat plasma
was spiked with the four drugs at 1000ngml¡1. Several
dilution approaches were evaluated, including direct
assay of 100 ml plasma, direct assay of 25ml plasma
(dilution factor of 4) and 25 ml spiked plasma plus 75ml
blank plasma (dilution factor of 4). These synthetic
samples were transferred into the 1.1-ml polypropylene
tubes in 96-rack format by manual transfer and assayed
(n ˆ 3) for a comparative assessment of parallelism.
Results and discussion
Description of integrated sample handling process
A pharmacokinetic cassette study typically consists of a
dosing solution of three to six compounds that are dosed
orally in three animals and intravenously in three other
animals. The total number of samples generated is 30± 60
depending on the number of time points desired. The
time spent in labelling, decapping and transferring
samples to alternate formats is often signi® cant. Use of
the 96-well format can drastically decrease the need for
these steps, so it seems likely that integration of study
design, sample collection and bioanalytical sample prep-
aration would improve the eæ ciency of the preclinical
drug discovery process.
Although automatic liquid-handling workstations now
replace manual transfer [7± 9], they required a standard
sample format such as 96- or 384 wells for maximum
eæ ciency [13]. Traditionally, in drug disposition studies,
biological ¯ uids (plasma, serum, urine, etc.) are collected
in individual, capped tubes or bottles. Each tube is
labelled individually with the collection time and animal
number before dosing. The volumes of samples are
varied. To work around the transfer of biological ¯ uid
samples from individual tubes to 96-well plates, it is
possible either to: (1) perform manual transferal of
samples, (2) use a liquid-handling workstation to transfer
samples or (3) generate initially and deliver samples
directly to a 96-well format. In our laboratories, each
approach has been used to some extent, with manual
transferal being the least desirable. The use of a liquid-
handling workstation such as the Packard Multiprobe
has shown some utility in transferring samples from
individual vials to a 96-well plate. Most recently, how-
ever, we have adopted the latter approach: the initial
generation and delivery of samples directly in a 96-well
plate. Although not applicable to all types of sample
matrices, most notably tissue samples, this approach can
streamline the sample-preparation approach by eliminat-
ing one or more sample transfer steps and by allowing 96-
well sample preparation to proceed more eæ ciently.
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2Because 96 wells is a universal format that ® ts various
automatic workstations, it can be built into those steps
preceding bioanalysis, including study design and sample
collection. Figure 1 depicts an integrated sample/infor-
mation ¯ ow for a typical discovery phase ex vivo experi-
ment such as a cassette-dosing experiment. In this
scheme, a discovery scientist designs a protocol and
builds a sample list that is sent electronically to an animal
models group. The animal models group executes the
dosing protocol, collects and delivers samples to a 96-well
plate along a prede® ned plate map (® gure 2). At this
point, some of the sample locations in the 96-well plate
remain vacant to accommodate standards and controls
which will be added later. From this point, the samples
remain in the 96-well format, although they may be
frozen, thawed, centrifuged, automatically transferred
or otherwise processed in parallel by the bioanalytical
chemist. After sample processing, a 96-well plate is
delivered to an autosampler and injected into the LC/
MS/MS system for separation, detection and quantita-
tion. Quantitation results are reported to a pharmacoki-
neticist in a format that has been previously de® ned by
the sample list and study protocol. This approach oå ers a
cogent, streamlined approach to sample collection and
data handling for most discovery-phase experiments.
Similar processes have been created for the collection of
CACO-2 and other in vitro experiments.
The 96-well map (® gure 2) is recommended here for any
study where samples are to be harvested. If designed
correctly, this map can provide a blueprint or plan for
study design, sample collection, sample assay, data re-
porting and data-processing structures. The standard 96-
well plate has eight rows, each containing 12 wells in
each row. In our model, samples from orally dosed rats
[1± 3] were arranged in rows A± C. Samples from the
three intravenously dosed rats [4± 6] were arranged in
rows D± F. In each row, time points were assigned (e.g.
® rst well for predose, second well for 15-min collection,
third well for 30-min collection, etc.). The collection
volume may also be labelled in the map or in an
accompanying spreadsheet. The 12 wells in rows G and
H are reserved for standards, blanks or quality controls as
needed.
Although the 96-well or similar format is essential to the
plan, 1.1-ml tubes were selected for containment of indi-
vidual samples. The ® rst consideration behind this deci-
sion was sample stability: samples can be capped and
placed into a freezer in the 96-well format immediately
after each time-point is collected. Without individual
tubes, an entire plate would need to be put in and pulled
out of the freezer repeatedly. Any associated freezing or
thawing could cause analyte degradation and clot for-
mation in plasma.
A second consideration, as detailed in [15], is the ability
to do automated or semi-automated extraction directly
within the 96-well format. Liquid extraction is especially
facilitated by individual tubes containing samples. A 96-
well plate containing such tubes is placed in one stage of
the Tomtec and a semi-automated liquid± liquid extrac-
tion is performed. In this strategy, no sample format
conversion, labelling or randomization is necessary so
that the time required for bioanalysis is greatly improved.
In this way, a higher degree of integration and streamlin-
ing of the in vivo portion of the drug-discovery process is
achieved.
Figure 1. Conceptual diagram of the integrated sample-handling process for discovery bioanalysis.
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3Parallelism studies
High level samples (15, 30min and 1h) need to be
diluted before assay. The precision and accuracy of
several dilution methods were compared. The standard
curve was constructed from 1 to 2000nmmg¡1 and a
relatively high concentration (1000ngml¡1 of drugs I±
IV) was chosen for the test. In the ® rst approach, 100ml
plasma was directly assayed without dilution. In the
second approach, 25ml plasma was directly extracted
and a dilution factor of 4 was used. In the third
approach, 75ml blank plasma was added to 25 ml of each
plasma sample and a dilution factor of 4 was again used.
In each case, three replicates were tested. The results
(table 1) suggest that the three approaches yielded results
that were statistically indistinguishable and gave accep-
table precision (< 2% RSD, except drug IV at 100ml
straight) and accuracy (generally < 7:2% relative error,
except for drug IV at 25 ‡ 75ml blank). The second
approach is commonly used in our laboratory because
it oå ers equal performance with a smaller number of
dilution steps. The reliability of this approach appears to
be excellent, while volume aliquoting is reduced. This
experiment has practical importance in terms of simplify-
ing the analytical procedure and in providing guidance
in the exact volume of sample necessary for collection. It
seems likely that using a reduced sample volume without
diluting plasma will be useful for other compounds in
similar matrices.
Quantitative comparison of exact-volume-delivered samples and
volume-transferred samples
To convert samples to a 96-well format automatically, a
MultiProbe II or similar workstation is commonly used
because of its ¯ exibility, good precision and accuracy. An
evaluation of the performance of transferring biological
samples such as plasma and serum was conducted to
estimate precision and accuracy. Twelve individual tubes
were weighted before and after transfer of 100ml plasma
or serum. The imprecision associated with these transfers
was < 0:5% RSD for rat plasma using the multiprobe
after brief centrifugation. The imprecision (RSD%) for
manual transfers was 2% RSD.
A comparison study between the collection of exact
volumes of plasma and the collection of unknown
(total) volumes of plasma was performed. For the
exact-volume experiment, volumes of plasma were col-
lected (25 ml at 30 min and 1h, 100ml at other time-
Figure 2. Prede¢ned 96-well plate map, which can give details of dosing protocol and sample collection.
Table 1. Quantitative comparison (n= 3) of three dilution approaches for high concentration sample assay.
100·l, no blank plasma added 25·l, no blank plasma added 25·l‡75·l blank plasma
Compound* Conc. RSD% RE% Conc. RSD% RE% Conc. RSD% RE%
I 1023 0.5 2.3 928 1.1 77.2 975 1.7 72.5
II 1013 1.7 1.3 1020 1.6 2.0 1049 1.4 4.9
III 1007 0.8 0.7 892 0.6 710 954 1.4 74.6
IV 977 5.6 72.3 1056 1.3 5.6 808 1.1 719
*I, dephenhydramine; II, desipramine; III, chlorpheniramine; IV, trimipramine. Samples contained 1000ngml¡1 of each compound
spiked into blank plasma.
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4points) into a 96-well tube rack. In the total-volume
approach, ¹ 200 ml plasma was harvested and stored in
the 96-well tube rack format. Subsequently, 50ml of each
sample was transferred by MultiProbe from the original
collection vessel to a new 96-well tube rack. To compare
the results of these diå erent procedures, the post-dose
concentrations of drugs I± IV were determined (® gure 3).
The same pharmacokinetic pro® le was obtained for each
example compound. Diå erences in plasma levels between
each of the four compounds ranged from 0.5 to 40%, but
averaged < 12:5%. The high degree of similarity in
concentrations obtained by the two approaches sub-
stantiates the reliability and applicability of the inte-
grated sample-handling process.
Brief comparison of serum and plasma
A comparison of the sample-handling properties between
serum and plasma was made for human and non-human
ex vivo samples. Results of transfers using fresh serum or
heparinized plasma were comparable: no clots were
visible and none were detected with the clot-sensing
mechanism. All transfers were successful, with variance
of < 1% for 100-ml aliquots. Upon one freeze± thaw (FT)
cycle, the sera remained clear, whereas all plasma tubes
contained some turbidity. Visual inspection showed that
many plasma tubes also contained some clotted material.
Statistical evaluation of 100-ml transfers of all plasma and
sera, both fresh and frozen, produced similar precision
(n ˆ 47 each, %RSDˆ1.64% and 0.92%, respectively).
However, an important factor was the failure rate for
transfers. All transfers with sera were successful regardless
of the fresh or frozen history of the samples. Transfers of
frozen plasma samples from ® ve of six patients contained
clots that were detected by the clot sensor of the Multi-
probe II. In some cases, the clotted samples were trans-
ferred successfully after several attempts. However, even
when transfers of clotted samples were successful, preci-
sion sometimes was adversely aå ected. One of the most
important ® ndings of these studies was that when sample
volume was limited, the presence of clots had the poten-
tial for a signi® cant eå ect on precision and accuracy of
automated transfers.
In contrast, transfers of all previously frozen plasma
samples in which sample volume was not limited were
successful when a centrifugation (14000rpm) step was
performed before the transfer. Precision and success rates
using centrifuged plasmas were comparable with those of
sera. Centrifugation did not provide additional improve-
ment for the transfer of sera.
To evaluate the drug concentrations in serum and
plasma, both matrices were collected at all time-points
of the study protocol. The comparison of serum and
plasma concentrations at each time point is shown in
® gure 4. The average diå erences in the four compounds
Figure 3. Comparison of drug concentrations for four example compounds after sample processing by two approaches: 1, exact volumes of
plasma delivered to the sample collection tubes in a 96-tube rack; 2, post-collection transfer of plasma to a 96-tube rack by MultiProbe.
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5between serum and plasma were: diphenhydramine,
7.2%; desipramine, 22%; chlorpheniramine, 3.3%; and
trimipramine, 14%. The results indicate that concentra-
tions from serum and plasma were equivalent to within
the limits of experimental variability (n ˆ 3). Concentra-
tion-related pharmacokinetic parameters obtained from
serum and plasma (table 2) agreed well. Because of the
limited time-points, other pharmacokinetic parameters
such as t1=2 were not compared.
In addition to the concern about clots in plasma, another
issue was raised during the study. Lipid layers were
frequently observed as an upper layer on samples,
which aå ected the experimental results. This issue was
addressed by using the MultiProbe II to control the
transfer tip at the surface of the sample. A liquid sensor
® rst identi® ed contact with the sample surface, then the
program controlled the tip descent to an additional
speci® ed distance. Plasma samples from some high-fat
rabbit plasma samples produced a considerable (25± 50%
of the volume) layer upon standing for several hours at
room temperature. Lipids could be handled by directing
the tip through the top layer, but this distance would
have to be determined by inspection of the operator as
the clot or liquid detection was not eå ective at diå er-
entiating a lipid layer.
Figure 4. Comparison of analyte concentrations in plasma and serum samples. Plasma and serum samples were collected from the same
animal. The average concentrations of three animals at di¡erent time points are shown, where error bars are the SD among the three animals.
Table 2. Characteristic pharmacokinetics parameters comparison from plasma and serum.
Bioavailability (%) Cmax(ngml
¡1)
Test compound Plasma Serum Plasma Serum
Chlorpheniramine (I) 31 § 4:1 31 § 4:7 233 § 12 260 § 42:7
Desipramine (II) 26 § 10:4 26 § 5:4 184 § 54 210 § 40
Diphenhydramine (III) 1:6 § 0:66 1:7§ 0:4 16 § 2:4 16 § 4:3
Trimipramine (IV) 3:9 § 2:1 3:7§ 0:3 27 § 12:9 29 § 8:6
Data are the average of three rats §SD of three rats. Data for plasma and serum were obtained from diå erent doses.
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6Although the issue about the lipid layer in centrifuged
plasma can be addressed, a caveat appears to be the need
to identify the minimum distance for additional tip
movement. This is a particular issue in cases where
sample volume is limited because a maximum distance
cannot be used by default. If the tip descends too far into
the sample after sensing the liquid level, it could disturb a
centrifuged clot, thus causing an error.
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